Edition:
India

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

5.47USD
12 Nov 2019
Change (% chg)

$0.09 (+1.58%)
Prev Close
$5.38
Open
$5.33
Day's High
$5.91
Day's Low
$5.26
Volume
1,633,427
Avg. Vol
1,084,454
52-wk High
$32.03
52-wk Low
$2.93

Latest Key Developments (Source: Significant Developments)

Kenneth Griffin Reports 7.0% Passive Stake In Clovis Oncology Inc
Friday, 16 Aug 2019 

Aug 16 (Reuters) - Clovis Oncology Inc ::KENNETH GRIFFIN REPORTS 7.0% PASSIVE STAKE IN CLOVIS ONCOLOGY INC AS OF AUGUST 9 - SEC FILING.  Full Article

Clovis Oncology To Offer $225 Million Of Convertible Senior Notes
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY TO OFFER $225 MILLION OF CONVERTIBLE SENIOR NOTES.CLOVIS ONCOLOGY INC - INTENDS TO OFFER $225 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS CONVERTIBLE SENIOR NOTES DUE 2024.CLOVIS ONCOLOGY - ALSO EXPECTS TO GRANT INITIAL PURCHASERS A 13-DAY OPTION TO PURCHASE UP TO $33.75 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL NOTES.  Full Article

Clovis Oncology Says On June 14, Co, Antipodean Domestic Partners Entered Into An Agreement
Monday, 17 Jun 2019 

June 17 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY INC - ON JUNE 14, CO, ANTIPODEAN DOMESTIC PARTNERS ENTERED INTO AN AGREEMENT.CLOVIS ONCOLOGY INC - AGREEMENT TO SETTLE LAWSUIT FILED BY ANTIPODEAN AGAINST CO, CERTAIN OF ITS OFFICERS AND DIRECTORS.CLOVIS ONCOLOGY INC - CO WILL PAY TO ANTIPODEAN $4 MILLION IN CASH AND $21 MILLION IN SHARES OF STOCK OF COMPANY.CLOVIS ONCOLOGY INC - ANTIPODEAN WILL DISMISS PENDING LAWSUIT AND RELEASE CO, ITS OFFICERS AND DIRECTORS AND UNDERWRITERS FROM ANY POTENTIAL LIABILITY.CLOVIS ONCOLOGY INC - ANTIPODEAN HAS INFORMED CO THAT IT MAY ESTABLISH A HEDGING POSITION IN RESPECT OF SETTLEMENT SHARES.  Full Article

Clovis Oncology Announces Interim Results From Rubraca Phase 2 Study In Advanced Pancreatic
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES INTERIM RESULTS FROM RUBRACA® (RUCAPARIB) PHASE 2 STUDY IN ADVANCED PANCREATIC CANCER AND NONCLINICAL DATA IN MULTIPLE SOLID TUMOR TYPES FOR RUCAPARIB AND LUCITANIB PRESENTED AT AACR 2019.CLOVIS ONCOLOGY INC - IS EVALUATING A POTENTIAL CLINICAL AND REGULATORY PATH FORWARD FOR RUBRACA IN PANCREATIC CANCER.  Full Article

Armistice Capital Llc Reports A Stake Of 3.8 Percent In Clovis Oncology
Saturday, 9 Mar 2019 

March 8 (Reuters) - Armistice Capital Llc::ARMISTICE CAPITAL, LLC REPORTS A STAKE OF 3.8 PERCENT IN CLOVIS ONCOLOGY AS OF FEB 28, 2019 - SEC FILING.ARMISTICE CAPITAL, LLC HAD PREVIOUSLY REPORTED A 9.8% STAKE IN CLOVIS ONCOLOGY INC AS OF OCTOBER 24, 2018 - SEC FILING.  Full Article

Clovis Oncology Q4 Adjusted Loss Per Share $1.88 Excluding Items
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES 2018 OPERATING RESULTS.Q4 ADJUSTED LOSS PER SHARE $1.88 EXCLUDING ITEMS.Q4 EARNINGS PER SHARE ESTIMATE $-1.73 -- REFINITIV IBES DATA.QTRLY PRODUCT REVENUE $30.4 MILLION VERSUS $17.0 MILLION.  Full Article

Clovis Oncology Announces European Commission Authorization Of Rubraca Tablets
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES EUROPEAN COMMISSION AUTHORIZATION OF RUBRACA®▼ (RUCAPARIB) TABLETS AS MAINTENANCE TREATMENT FOR WOMEN WITH RELAPSED OVARIAN CANCER.PLANS ITS INITIAL LAUNCH OF RUCAPARIB AS A MAINTENANCE THERAPY IN GERMANY IN Q1 2019.EUROPEAN COMMISSION APPROVAL EXPANDS RUCAPARIB'S INDICATION BEYOND INITIAL MARKETING AUTHORIZATION IN EUROPE GRANTED IN MAY 2018.RUCAPARIB IS NOW AVAILABLE TO PATIENTS REGARDLESS OF THEIR BRCA MUTATION STATUS.  Full Article

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology’s Rubraca Tablets
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Clovis Oncology Inc ::CHMP GRANTS POSITIVE OPINION FOR NEW INDICATION OF CLOVIS ONCOLOGY’S RUBRACA®▼ (RUCAPARIB) TABLETS AS MAINTENANCE TREATMENT FOR WOMEN WITH RELAPSED OVARIAN CANCER.CLOVIS ONCOLOGY INC - EUROPEAN COMMISSION (EC) MARKETING AUTHORIZATION IS ANTICIPATED Q1 2019.  Full Article

Clovis says Positive Outcome In European Opposition Proceeding Related To Rubraca
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES POSITIVE OUTCOME IN EUROPEAN OPPOSITION PROCEEDING RELATED TO RUBRACA®.CLOVIS ONCOLOGY INC - CLAIMS DIRECTED TO RUBRACA( )CRYSTALLINE FORMS UPHELD.CLOVIS ONCOLOGY INC - PATENT PROTECTION FOR RUBRACA IN EUROPE CONFIRMED UNTIL AT LEAST 2031.CLOVIS - RUBRACA COMMERCIAL FORM ENTITLED TO EUROPEAN REGULATORY EXCLUSIVITY UNTIL AT LEAST 2028 (2029 IF INDICATION IN SECOND TUMOR TYPE IS APPROVED).  Full Article

Clovis Oncology Reports Q2 Loss Per Share $1.94
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Clovis Oncology Inc ::CLOVIS ONCOLOGY ANNOUNCES SECOND QUARTER 2018 OPERATING RESULTS.Q2 ADJUSTED LOSS PER SHARE $1.55 EXCLUDING ITEMS.Q2 LOSS PER SHARE $1.94.Q2 EARNINGS PER SHARE VIEW $-1.88 -- THOMSON REUTERS I/B/E/S.QUARTERLY PRODUCT REVENUE, NET $23.76 MILLION VERSUS $14.62 MILLION.  Full Article